FDA Clears MindChild Medical’s Fetal Monitor

In February we reported that MBBP client MindChild Medical Inc. had filed for a Pre-Marketing Notification Application (510(k)) with the U.S. Food and Drug Administration for its non-invasive fetal heart rate monitor, MERIDIAN™.  On September 25, MindChild announced that the FDA has cleared MERIDIAN™ and anticipates it entering the U.S. markets in the near future. Bill Edelman, CEO of …

Continue reading FDA Clears MindChild Medical’s Fetal Monitor